Cubist Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUBIST, and when can generic versions of CUBIST drugs launch?
CUBIST has seven approved drugs.
There are thirty US patents protecting CUBIST drugs.
There are three hundred and forty-one patent family members on CUBIST drugs in fifty-three countries and fifty-five supplementary protection certificates in eighteen countries.
Summary for Cubist
International Patents: | 341 |
US Patents: | 30 |
Tradenames: | 6 |
Ingredients: | 5 |
NDAs: | 7 |
PTAB Cases with Cubist as patent owner: | See PTAB cases with Cubist as patent owner |
Drugs and US Patents for Cubist
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | 8,906,898 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | 8,685,957 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | 10,065,947 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | 8,420,676 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Cubist Pharms Llc | DIFICID | fidaxomicin | TABLET;ORAL | 201699-001 | May 27, 2011 | AB | RX | Yes | Yes | 7,906,489*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cubist
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 5,912,226 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 8,058,238 | ⤷ Try a Trial |
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 6,469,030 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 5,912,226 | ⤷ Try a Trial |
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 5,250,542 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUBIST drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2015-05-27 |
➤ Subscribe | Capsules | 12 mg | ➤ Subscribe | 2017-06-16 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-11-19 |
International Patents for Cubist Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20150114498 | ⤷ Try a Trial |
Japan | 5468388 | ⤷ Try a Trial |
Hungary | S1600008 | ⤷ Try a Trial |
Malaysia | 156354 | ⤷ Try a Trial |
South Korea | 100972542 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cubist Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1699784 | C 2015 035 | Romania | ⤷ Try a Trial | PRODUCT NAME: TEDIZOLIDOPTIONAL SUB FORMA DE ESTER, IN PARTICULAR FOSFATUL SAU O SARE ACCEPTABILA FARMACEUTIC AACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/15/991; DATE OF NATIONAL AUTHORISATION: 20150323; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/991; DATE OF FIRST AUTHORISATION IN EEA: 20150323 |
1699784 | 15C0062 | France | ⤷ Try a Trial | PRODUCT NAME: TEDIZOLIDE,EVENTUELLEMENT SOUS LA FORME D'UN ESTER ,EN PARTICULIER UN PHOSPHATE,OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/991 20150325 |
1539977 | 300727 | Netherlands | ⤷ Try a Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE |
1539977 | 15C0028 | France | ⤷ Try a Trial | PRODUCT NAME: FIDAXOMICINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111207 |
1699784 | 675 | Finland | ⤷ Try a Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.